SAB Biotherapeutics, Inc. Common Stock (SABS) is a publicly traded Healthcare sector company. As of May 21, 2026, SABS trades at $3.63 with a market cap of $272.21M and a P/E ratio of 16.77. SABS moved +3.66% today. Year to date, SABS is -1.60%; over the trailing twelve months it is +99.71%. Its 52-week range spans $1.00 to $6.60. Analyst consensus is strong buy with an average price target of $12.17. Rallies surfaces SABS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
SAB Biotherapeutics, Inc. Common Stock (SABS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. SABS moved +3.66% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $3.63 |
| Market Cap | $272.21M |
| P/E Ratio | 16.77 |
| EPS | $0.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.60 |
| 52-Week Low | $1.00 |
| Volume | 47 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $13.27M |
| Gross Margin | 0.00% |
7 analysts cover SABS: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.17.